Bioavailability of Ubiquinol in Huntington Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals.

Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ ("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)

NCT00920699

Huntington's Disease

COMPLETED PHASE2

Coenzyme Q10 in Huntington's Disease (HD)

NCT00608881

Huntington's Disease

TERMINATED PHASE3

Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers

NCT03061513

Parkinson Disease

COMPLETED PHASE2

Parkinson's Disease Treatment With Coenzyme Q10

NCT00004731

Parkinson's Disease

COMPLETED PHASE2

Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease

NCT00180037

Parkinson's Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Huntington Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ubiquinol

up to 600 mg per day, oral capsules for 8 weeks

Group Type EXPERIMENTAL

ubiquinol

Intervention Type DIETARY_SUPPLEMENT

up to 600 mg per day, oral capsules for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ubiquinol

up to 600 mg per day, oral capsules for 8 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have manifest Huntington disease
* Be 18 years of age or older
* Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline visit
* Be on a steady dose of all concomitant medications for at least 30 days prior to the baseline visit

Exclusion Criteria

* Have a history of intolerability of sensitivity to CoQ
* Have an unstable medical or psychiatric illness
* Be pregnant or breastfeeding; women of childbearing age must use reliable contraception

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No